Zoetis (ZTS) Income from Continuing Operations (2012 - 2026)
Zoetis (ZTS) reported Income from Continuing Operations of 601000000.0 for Q1 2026, little changed year-over-year from 602000000.0 in Q1 2025, and little changed quarter-over-quarter from 603000000.0 in Q4 2025.
Zoetis (ZTS) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Income from Continuing Operations data on file, last reported at 601000000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 601000000.0, changed 0.17% year-over-year; the trailing twelve-month figure through Mar 2026 was 2643000000.0 (up 5.76% YoY), and the FY2025 annual result was 2673000000.0, up 7.09% from the prior year.
- Income from Continuing Operations was little changed at 601000000.0 in Q1 2026 per ZTS's latest filing, from 603000000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 721000000.0 in Q3 2025 and troughed at 460000000.0 in Q4 2022.
- A 5-year average of 599529411.76 and a median of 599000000.0 in 2024 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 26.65% in 2023 and fell as far as 7.24% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 460000000.0 in 2022, then gained by 13.7% to 523000000.0 in 2023, then grew by 11.09% to 581000000.0 in 2024, then gained by 3.79% to 603000000.0 in 2025, then dropped by 0.33% to 601000000.0 in 2026.
- Business Quant data shows ZTS's Income from Continuing Operations at 601000000.0 in Q1 2026, 603000000.0 in Q4 2025, and 721000000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | 52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 601.00 Mn |
| Dec 31, 2025 | 603.00 Mn |
| Sep 30, 2025 | 721.00 Mn |
| Jun 30, 2025 | 718.00 Mn |
| Mar 31, 2025 | 602.00 Mn |
| Dec 31, 2024 | 581.00 Mn |
| Sep 30, 2024 | 692.00 Mn |
| Jun 30, 2024 | 624.00 Mn |
| Mar 31, 2024 | 599.00 Mn |
| Dec 31, 2023 | 523.00 Mn |
| Sep 30, 2023 | 596.00 Mn |
| Jun 30, 2023 | 670.00 Mn |
| Mar 31, 2023 | 551.00 Mn |
| Dec 31, 2022 | 460.00 Mn |
| Sep 30, 2022 | 528.00 Mn |
| Jun 30, 2022 | 529.00 Mn |
| Mar 31, 2022 | 594.00 Mn |
| Dec 31, 2021 | 413.00 Mn |
| Sep 30, 2021 | 552.00 Mn |
| Jun 30, 2021 | 511.00 Mn |